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This article examines the use of injectable semaglutide in the treatment of type 2 diabetes. 
A brief description of the global problem posed by type 2 diabetes is followed by 
consideration of the glucagon-like peptide 1 receptor agonist class of glucose lowering 
therapies. The focus is then shifted to semagltuide and a description of the large phase 3 
pre-approval trial programme known as SUSTAIN. There is consideration of glucose control, 
the primary end-point of the phase 3 programme as well as secondary end-points such as 
weight and blood pressure. There follows a précis of the cardiovascular outcomes trial for 
subcutaneous semaglutide (SUSTAIN 6) and the post-approval publications. The expert 
opinion section discusses the position of semaglutide and the pros and cons versus other 
once weekly GLP-1RAs and finally the development of an oral version of semaglutide, which 




Diabetes mellitus (DM) is a common group of metabolic diseases, which are characterised 
by persistent elevation of plasma glucose levels. The two major forms of DM are termed 
type 1 and type 2 and both are associated with development of microvascular complications 
affecting the eyes, kidneys and nerves (termed retinopathy, nephropathy and neuropathy) 
as well as an increased risk of cardiovascular (CV) disease. Type 2 DM (T2DM) is 
characterized by insulin resistance and progressive loss of insulin secretion by beta-cells in 
the pancreatic islets of Langerhans. (REF 1). The underlying driver for T2DM in most cases is 
being overweight or obese and the increasing prevalence of obesity is the reason that the 
incidence continues to rise. Termed the ‘diabetes epidemic’, it is estimated that around 10% 
of the global adult population are affected by T2DM (REF 2). In theory, lifestyle modification 
should both prevent and be an effective treatment for T2DM but in real life changes in diet 
and exercise are difficult to implement. This has promoted the development of 
pharmacologic glucose lowering therapies and in Europe there are currently eight different 
classes of these medications.  
 
The glucagon-like peptide 1 (GLP-1) receptor agonist class of glucose lowering medicines 
was introduced into clinical practice in 2006. These agents stimulate the GLP-1 receptor and 
this enhances pancreatic insulin secretion whilst reducing the production of glucagon, both 
in a glucose-dependent manner. GLP-1 receptor agonists (GLP-1RAs) can also slow gastric 
emptying and, probably via an effect on the central nervous system, increase satiety, both 
of which can promote weight loss. These agents are currently available as injectable 
peptides which, unlike endogenous GLP-1, are resistant to degradation by the ubiquitous 
enzyme dipeptidyl peptase-4 (DPP-4). The major side-effects of this class are gastro-
intestinal (GI) with nausea, vomiting and diarrhoea being most common (although these 
typically diminish over time).  
 
Exenatide was the first GLP-1RA to be launched (Byetta®) and was based on the exendin-4 
molecule; due to its short half-life it was administered twice daily with meals (REF 3).  In 
2011 the European Medicines Agency authorised a once-weekly (QW) version of exenatide 
[Bydureon®], the first long-acting GLP-1RA (REF 4) and in 2020 there are two other 
commercially available once weekly GLP-1RA therapies, dulaglutide (REF 5) and semaglutide 
(REF 6). 
 
Semaglutide (Ozempic®) was approved by the United States Food and Drug Administration 
(FDA) in 2017 and by the European Medicines Agency (EMA) in 2018, as an addition to diet 
and exercise in people with poorly controlled T2DM (REF 7).  Unlike exenatide, this molecule 
is based on human GLP-1 and has 94% homology with this molecule, differing only by two 
amino acids. The substitution at position 8 (alanine to alpha-aminoisobutyric acid) protects 
against DPP4 degradation whilst an 18 carbon fatty di-acid chain attached via a spacer to 
the lysine amino acid at position 26 provides strong binding to albumin (figure 1). These 
modifications facilitate the prolongation of action, with an elimination half-life of 
approximately 168 hours. Semaglutide is delivered as a clear, colourless solution which does 
not require resuspension. It is initiated at a dose of 0.25mg QW titrated after four weeks to 
a maintenance dose of 0.5mg or, with further up-titration, 1.0mg QW. Semaglutide is 
extensively metabolized and the metabolites are predominantly excreted by the renal tract 
and to a lesser extent in the faeces (REF 8) Exposure to semaglutide is not significantly 
affected by severe renal impairment, nor impaired liver function (REF 9). 
 
 




In healthy adults, subcutaneous administration of one dose of semaglutide 0.5 mg reaches a 
maximum concentration (Cmax) in 24–56 hours  (REFS 8,9). Dose-escalation studies using 
weekly semaglutide 0.25 mg doses for four weeks, followed by 0.5 mg (four weeks) and 
then 1.0 mg (five weeks) showed a similar time to Cmax of 33–36 hours after the final 1.0 
mg dosing (REFS 10,11). Cmax and area under the plasma concentration–time curve (AUC) 
are similar following a single 0.5 mg dose and following the final 1.0 mg dose during a dose 
escalation (REFS 8,9,10,11). Subcutaneous bioavailability of semaglutide is 94%, which is the 




Semaglutide was intended to be an analogue of liraglutide with increased binding affinity 
for albumin, so as to allow for once-weekly dosing. Lau et al. showed in living pigs that the 
half-life of semaglutide following  intravenous administration was approximately 46 hours 
compared with 12 hours for liraglutide (REF 12). Semaglutide had a higher volume of 
distribution (0.102 L/kg versus 0.067 L/kg) and slower clearance (0.0016 vs. 0.0038 L/h/kg), 
indicative of enhanced binding to albumin. Mean residence time following subcutaneous 
administration of semaglutide was around 63 hours compared with 23 hours for liraglutide 




The metabolism of semaglutide was studied in an absorption, metabolism, and excretion 
study in seven healthy males who received a single subcutaneous dose of radiolabeled [3H]-
semaglutide (REF 8). Metabolite profiling showed that semaglutide is metabolized to six 
different metabolites labelled P1–P3 and P5–P7. P4 was the parent compound [3H]-
semaglutide and this was the primary component detected in plasma (82.6%). Semaglutide 
is metabolized by proteolytic cleavage of the peptide backbone and beta-oxidation of its 
fatty acid side chain. The concentrations of the metabolites declined over time, with only 
the parent compound being detected in plasma at 28 days after dosing. It is unknown if the 




In same study, the excretion of radiolabeled [3H]-semaglutide and its metabolites was also 
reported (REF 8). After 64 days of collection following the single subcutaneous dosing of 
0.5mg semaglutide, 75% of the dose was recovered. 53% was in urine, 18.6% in faeces and 
3.2% in expired air. The parent semaglutide molecule and 21 metabolites were detected in 
urine, and around 3% of the administered dose was found to be [3H]-semaglutide, with two 
metabolites (P6 and P7) each accounting for 14% of the administered dose, and all other 
metabolites accounting for <2% of the administered dose. The minimal amount of intact 
drug in the urine indicated that adjustment of dosing according to renal status would not be 
necessary. No parent drug was detected in faeces. 
 
In a phase 2 clinical trial, four hundred and fifteen subjects were randomised to 
subcutaneous semaglutide without dose escalation (0.1-0.8 mg QW) for twelve weeks or 
with dose escalation (0.4 mg steps to 0.8 or 1.6 mg over 1-2 weeks) (REF 16). The primary 
end-point was change in HbA1c from baseline; secondary end-points included change in 
body weight, safety, and tolerability.  Semaglutide dose-dependently reduced HbA1c from 
baseline (65 mmol/mol) by up to 18.6 mmol/mol and reduced body weight by as much as 
4.8 kg. Over 80% of patients achieved an HbA1c <53 mmol/mol. An open-label comparison 
with liraglutide 1.2mg and 1.8mg OD in the same study showed that HbA1c and weight 
reduction with semaglutide 1.6 mg were better but adverse events (AEs) and withdrawals 
were more frequent (REF 16). The incidence of nausea, vomiting, and withdrawal due to 
gastrointestinal AEs increased with semaglutide dose although most events were mild-to-
moderate, transient, and ameliorated by dose escalation. There were no major episodes of 
hypoglycaemia, few injection site reactions and no unexpected safety or tolerability 
concerns. On this basis, weekly semaglutide doses of 0.5 and 1.0 mg with a 4-week dose 
escalation were selected for the phase 3 assessments. 
 
The phase 3 clinical trial programme for semaglutide (table) 
 
Glucose control (figure 2) 
 
Phase 3 clinical trials of semaglutide were termed the ‘Semaglutide Unabated Sustainability 
in Treatment of Type 2 diabetes’ (SUSTAIN) programme and included 8,416 people with 
T2DM (REF 17). SUSTAIN was made up of six trials, each with a primary endpoint of change 
in glucose control (assessed by HbA1c) from baseline to the end of trial (EOT). In addition, a 
cardiovascular outcome trial (CVOT) was performed. Semaglutide was assessed in patients 
across the entire spectrum of T2DM, from treatment-naïve, through combinations with oral 
glucose lowering agents (metformin, sulphonylureas and thiazolidinediones) and with 
insulin. All of the studies were randomised controlled trials (RCTs) assessing the glucose 




In this study, semaglutide was compared with placebo injection in people with T2DM 
treated with only diet and exercise (i.e. not receiving any other glucose lowering 
therapies)(REF 18). Participants had an average diabetes duration of 4.2 years and mean 
body mass index (BMI) of 32.9 kg/m2. The mean baseline HbA1c was 64.5 mmol/mol, which 
after 30 weeks fell by 16.0 mmol/mol with semaglutide 0.5 mg QW and by 17.1 mmol/mol 
with semaglutide 1.0 mg QW, both reductions being significantly greater than placebo (-0.2 
mmol/mol). This led to significantly more subjects achieving an HbA1c<53 mmol/mol with 
semaglutide 0.5mg and 1.0mg (74% and 72% respectively) compared with placebo (25%). 
 
SUSTAIN 2 
In the SUSTAIN 2 study, semaglutide 0.5 mg and 1.0 mg QW were compared with oral 
sitagliptin 100 mg (a DPP4-inhibitor) once daily (OD) over a 56 week period (REF 
19). Subjects were being treated with other glucose lowering therapies (predominantly 
metformin) and had a baseline HbA1c of 64.1–65.8 mmol/mol. The average duration of 
T2DM was 6.4–6.7 years and mean BMI was 32.5 Kg/m2. At EOT the HbA1c was significantly 
lower in the semaglutide 0.5 mg (14.4 mmol/mol) and 1.0 mg (17.6 mmol/mol) groups 
compared with a 6.0 mmol/mol reduction with sitagliptin. 
 
SUSTAIN 3 
This trial was a comparison of semaglutide 1.0mg QW with the once-weekly GLP-1RA 
exenatide extended release (exenatide ER) 2.0 mg (REF 20). Participants were also treated 
with other glucose lowering therapies, mainly metformin (96.3–96.8%) and sulphonylureas 
(44.8–51.4%). The average diabetes duration of trial subjects was 9.2 years and mean BMI 
was 33.8 kg/m2. At EOT (56 weeks) HbA1c was reduced by 16.8 mmol/mol in the 
semaglutide arm compared with 10.0 mmol/mol for exenatide ER group and this difference 
was statistically significant in favour of semaglutide. 
 
SUSTAIN 4 
Here, semaglutide was compared with the long-acting insulin analogue, insulin glargine 
(U100 concentration (REF 21). People with T2DM who were sub-optimally controlled on a 
stable dose of metformin and/or sulphonylureas (but naïve to insulin) were assigned to 
semaglutide 0.5 mg or 1.0 mg QW or glargine.  The starting dose of glargine was 10 units OD 
and this was titrated to a fasting plasma glucose target of 4.0–5.5 mmol/l. Trial recruits had 
an average duration of diabetes of 8.6 years and a mean BMI of 33.0 Kg/m2. The mean 
HbA1c at baseline was 65.8 mmol/mmol and at EOT (30 weeks) fell by 13.2 mmol/mol with 
semaglutide 0.5 mg QW and 17.9 mmol/mol with semaglutide 1.0 mg QW. Both of these 
reductions were significantly better than that achieved by glargine (9.1 mmol/mol) although 
the mean insulin dose was modest (29.2 units OD) and the achieved fasting plasma glucose 
was 7.1 mmol/l (i.e. above the pre-specified target). 
 
SUSTAIN 5 
In the SUSTAIN 5 study, semaglutide 0.5 mg QW and 1.0mg QW were investigated as an 
add-on to basal insulin therapy and compared with placebo (REF 22). Trial recruits were 
already  treated with a stable dose of basal insulin (neutral protamine Hagedorn [NPH], 
glargine, detemir or degludec) either alone or in combination with metformin.  The average 
diabetes duration was 13.3 years and daily basal insulin doses were 36.6–39.3 units. In 
those subjects with baseline HbA1c less than 64 mmol/mol, the insulin dose was reduced by 
20% so as to avoid hypoglycaemia; the insulin dose could then be up-titrated between 
weeks 10 and 16. The mean baseline HbA1c was 67.9 mmol/mol and at EOT (30 weeks) fell 
significantly more with semaglutide 0.5 mg QW (15.8 mmol/mol) and 1.0 mg QW (20.2 
mmol/mol) than with placebo (1.0 mmol/mol). These improvements in HbA1c were seen 
despite their being a reduction in insulin dose from baseline in both the semaglutide groups 
(0.5mg QW; mean 39.3 to 35.4 units OD and 1.0 mg QW; 37.4 to 31.5 units OD). 
 
SUSTAIN 7 
The SUSTAIN 7 trial was another head-to-head comparison with a weekly GLP-1RA, this time 
dulaglutide(REF 23). People with T2DM with suboptimal glycaemic control on metformin 
(minimum dose of 1.5g OD) were randomised to semaglutide 0.5 mg or 1.0 mg QW, or 
dulaglutide 0.75 mg or 1.5 mg QW. The average diabetes duration was 7.0–7.7 years and 
mean BMI was 33.1–33.7 kg/m2.  The baseline mean HbA1c was 66.1–67.2 mmol/mol and at 
EOT (40 weeks) was significantly reduced in all four treatment cohorts. Comparison of the 
low and high doses of each agent showed a significant benefit in glucose lowering for 
semaglutide over dulaglutide (semaglutide 0.5 mg QW 16.5 mmol/mol versus dulaglutide 
0.75mg QW 12.1 mol/moland semaglutide 1.0mg QW 19.4 mmol/mol versus dulaglutide 1.5 
mg 14.9 mmol/mol). 
 
Secondary endpoints - Body weight (figure 3)  
 
The effect of semaglutide on body weight was reported as a secondary endpoint in the 
SUSTAIN programme and both doses of semaglutide demonstrated significant reductions in 
weight after 30–56 weeks. Semaglutide 0.5 mg QW was associated with 3.5-4.6 Kg weight 
loss in the trials and this is equivalent to a 3.7–4.8% reduction of baseline body mass. At a 
dose of 1.0 mg QW, semaglutide achieved weight reductions of 4.5-6.5 Kg (4.7–7.0% 
baseline body mass). The observed reductions in weight with semaglutide 0.5 mg QW and 
1.0 mg QW were significantly better than those seen with comparators, placebo, sitagliptin 
100 mg OD and insulin glargine (REF 19). Semaglutide 1.0 mg QW also resulted in greater 
weight reductions than the other once weekly GLP-1RAs, exenatide ER and dulaglutide (REF 
20, 23). Significant weight loss was also seen when semaglutide was added to basal insulin 
therapy, at least partly due to the reduction in insulin dose in those subjects receiving 
semaglutide (REF 22). 
 
Secondary endpoints - Blood pressure and pulse rate  
 
In the SUSTAIN phase 3 clinical trial programme, treatment with semaglutide 0.5 mg QW 
was associated with a fall in systolic blood pressure (SBP) of 2.4-5.1 mm Hg whilst the 1.0 
mg QW dose led to a fall of  2.7-6.3 mm Hg. This effect was significantly greater than the 
comparators except for placebo in SUSTAIN 1 (REF 18) and dulaglutide in SUSTAIN 7 (REF 
23). Diastolic blood pressure was also lowered although to a lesser extent, and generally not 
significantly different from comparators (apart from SUSTAIN 7 where semaglutide achieved 
a larger reduction than dulaglutide (REF 23). 
 
Across the SUSTAIN programme, semaglutide was associated with an increase in pulse rate 
of 1–4 beats per minute, a finding which has been consistently observed with all GLP-1RAs 
(REF 24). In the head-to-head comparisons (SUSTAIN 3 and 7), semaglutide 1.0 mg QW had 
a greater increase in heart rate than dulaglutide 1.5 mg QW (4.0 versus 2.4 beats per 
min)(REF 23). 
 
Secondary endpoints – Other cardiovascular risk factors 
 
The impact of semaglutide on plasma lipids is marginal but where changes are seen, these 
are generally in a positive direction (i.e. favouring CV protection). In SUSTAIN 1 and 4, a 
significant reduction in total cholesterol and low-density lipoprotein (LDL) was reported (REF 
18, 21), whilst there were reductions in free fatty acids in SUSTAIN 1 and 3 (REF 18,20), and 
falls in  triglycerides in SUSTAIN 3 and 4 (REF 19,21). Finally, high-density lipoprotein (HDL) 
significantly increased and very low-density lipoprotein (VLDL) fell in subjects randomised to 
semaglutide in SUSTAIN 2 (REF 19). C-reactive protein (a biomarker for CV risk)(REF 25), was 
measured in SUSTAIN 2 and 4 and was found to be significantly reduced by semaglutide 
(both 0.5 mg  and 1.0 mg QW)(REF 19,21). 
 
SUSTAIN 6 – Cardiovascular outcomes trial 
 
In 2008 the United States FDA mandated that all new glucose lowering therapies should be 
subjected to a cardiovascular outcomes trial (CVOT) to demonstrate CV safety (REF 26). 
Semaglutide was assessed in the SUSTAIN 6 trial (REF 27), which was performed before drug 
approval and was, therefore, smaller and shorter than some other CVOTs for GLP-RAs, such 
as LEADER (liraglutide) (REF 28) and EXSCEL (exenatide ER)(REF 29). SUSTAIN 6 was a 
randomised, double-blind, placebo-controlled, multicentre study conducted between 2013-
2016. Subjects were allocated to semaglutide, 0.5 mg and 1.0 mg QW or volume-matched 
placebo, in addition to CV ‘standard of care’.  Standard of care promoted optimal 
management of blood pressure, lipids and use of anti-platelet therapies, as well as aiming 
for equivalent glucose lowering in each of the trial arms (so-called ‘glycaemic equipoise’ 
(REF 30)). SUSTAIN 6 enrolled 3,297 people with T2DM at high CV risk and was both event 
and time-driven, patients having a minimum of two years exposure to investigational 
medical product (IMP). Recruitment criteria were similar to those of the LEADER trial with 
two cohorts: 1) age ≥50 years and established CV disease (cerebrovascular disease, coronary 
heart disease, peripheral vascular disease, chronic kidney disease (stage 3 or higher), or 
chronic heart failure of New York Heart Association classes II–III); 2) age >60 years and one 
or more CV risk factors (for example, microalbuminuria, hypertension). The primary 
outcome was a composite of major cardiovascular events (MACE); CV death, non-fatal 
myocardial infarction or non-fatal stroke. Despite the attempt to achieve glycaemic 
equipoise (which led to more glucose lowering therapies being initiated in the placebo 
arms), semaglutide 0.5 mg QW and 1.0 mg QW significantly lowered HbA1c by 7.7 
mmol/mol and 11.1 mmol/mol respectively. Weight was also significantly reduced by 2.87-
4.35 Kg by semaglutide.  
 
The primary endpoint occurred in fewer people receiving semaglutide than placebo (6.6% vs 
8.9%) giving a hazard ratio (HR) of 0.74 (95% confidence intervals 0.58 – 0.95) which 
demonstrated statistically significant non-inferiority for the CV safety of semaglutide. A test 
for superiority of CV safety for semaglutide (which was not pre-specified) was also 
significant and was driven by a reduction in nonfatal stroke (seen in 1.6% of the patients in 
the semaglutide group versus 2.7% for placebo). Hospitalisation rates for heart failure were 
similar in the two groups. As a result of the SUSTAIN 6 trial, semaglutide is one of the 





In the SUSTAIN phase 3 trial programme, the rates of discontinuation of IMP due to adverse 
events (AEs) were low, amounting to  5–13% in SUSTAIN 1–5 and 7. There was a higher 
discontinuation rate in SUSTAIN 6 (around 20%) but this trial was of a much longer duration. 
Discontinuation rates was higher for semaglutide than placebo, sitagliptin and insulin 
glargine (SUSTAIN 2, 4 and 5), but were comparable in the head-to-head GLP-1RA studies 
(SUSTAIN 3 and 7). The predominant AEs of semaglutide were GI and are consistent with the 
known side-effects of this class of glucose lowering therapy (REF 18-23, 28,33).Nausea was 
reported by 11–24% of people receiving semaglutide, diarrhoea was reported by 5–19% and 
vomiting by 4–14%.  
 
Frequency of hypoglycaemia (severe, requiring third-party assistance, or confirmed blood 
glucose <3.1 mmol/L) was very low in SUSTAIN trials (1-2%) unless semaglutide was co-
administered with insulin or sulphonylureas (REF 18,19,23). In trials including these agents 
with their known potential for hypoglycaemia, rates were between 4–10.7% (REF 20-22). 
 
In the SUSTAIN 6 CVOT there was an increase in the rate of diabetic retinopathy (DR) events 
observed with semaglutide versus placebo (3.0% versus 1.8%, HR 1.76) and this was 
statistically significant (REF 27). The reason for this finding has not been fully explained, but 
interestingly there was no signal for increased DR in SUSTAIN 1-5 and 7, trials which 
excluded participants with active DR and had an upper threshold of HbA1c for inclusion. This 
has led to the suggestion that worsening of DR is caused by a rapid reduction in glucose 
levels in subjects with very poor glycaemic control and existing retinopathy (REF 34,35). It is 
perhaps of note that a non-significant increase in DR events was also seen in the CVOTs for 
liraglutide and dulaglutide (REF 28,36) consistent with an impact of potent glucose-
lowering. There was no evidence of deterioration in renal events in SUSTAIN 6, another 
long-term diabetes complication which is regarded as being microvascular, indeed the onset 
of new or worsening albuminuria was lower in semaglutide treated patients (REF 27). 
 
As has been extensively documented for liraglutide, serum amylase and lipase levels 
increased during exposure to semaglutide, however, the incidence of pancreatitis was low in 
the SUSTAIN programme (<1%) and similar to comparator treatments.  
 
Post-approval studies (table) 
 
Since semaglutide by injection (Ozempic®) was approved in the United States in 2017, the 
SUSTAIN trial programme has completed additional clinical trials, with three being published 
in 2019 (REF 37-39). These studies have confirmed the previously reported efficacy of 
semaglutide, in terms of glucose and weight lowering, without raising any new safety 
concerns. More importantly, they have provided additional data regarding the performance 
of semaglutide compared with other commonly used glucose-lowering therapies and in 
combination with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor.  
 
SUSTAIN 8 
This was a double-blind, parallel-group, RCT where people with sub-optimally controlled 
T2DM were assigned to semaglutide 1·0 mg QW or oral canagliflozin (an SGLT-2 inhibitor) 
300 mg OD(REF 37). Participants randomised to semaglutide had a significantly greater 
lowering of both HbA1c and body weight compared with those receiving canagliflozin 
(HbA1c estimated treatment difference [ETD]–5·34 mmol/mol and body weight ETD –1·06 
Kg). GI disorders, mainly nausea, were the most frequently reported AE with semaglutide, 
occurring in 47% of subjects; premature treatment discontinuation because of AEs occurred 
in 10% of semaglutide patients compared with 5% on canagliflozin. 
 
SUSTAIN 9 
This trial investigated the safety and efficacy of semaglutide 1.0 mg QW added to an SGLT-2 
inhibitor compared with placebo (REF 38). In addition to IMP and SGLT-2 inhibitor, 71·5% of 
trial participants were taking metformin and 12·9% a sulphonylurea. At EOT (30 weeks) 
semaglutide produced significantly larger reductions in mean HbA1c (ETD -15·55 mmol/mol) 
and body weight (-3·81 Kg). GI AEs were reported in 37·3% people in the semaglutide group 
and 13·2% for placebo. Hypoglycaemia (severe or blood glucose-confirmed) was reported in 
2.7% patients on semaglutide.  
 
SUSTAIN 10 
This study compared the safety and efficacy of semaglutide 1.0 mg QW with the most 
frequently prescribed dose of liraglutide in European clinical practice (1.2 mg OD)(REF 39). 
The trial was open label and included people with sub-optimally controlled T2DM on 1–3 
oral glucose lowering therapies. Mean HbA1c at EOT (30 weeks) fell from 66.1 mmol/mol to 
47.5 mmol/mol with semaglutide and to 55.2 mmol/mol with liraglutide (ETD 7.7 
mmol/mol) whilst the reduction in weight (ETD -3.83 Kg) also significantly favoured 
semaglutide. Both therapies had similar safety profiles, but with more frequent GI AEs with 




GLP-1RA therapies have been available for the treatment of people with T2DM since 2006 
and are being increasingly used by clinicians due to their efficacy in glucose lowering and 
weight reduction. There is also evidence for CV protection in GLP-1RAs which are analogues 
of human GLP-1.  
 
Semaglutide is the most recently approved GLP-1RA and has 94% homology with the human 
GLP-1 molecule.  It is one of three currently available GLP-1RAs which can be administered 
once weekly. It has been assessed in an extensive phase 3 clinical trial programme, spanning 
the continuum of people with T2DM from treatment naïve to those receiving insulin. It 
demonstrates high efficacy in reducing hyperglycaemia, as assessed by HbA1c, and has 
additional benefits of weight reduction and blood pressure lowering. In terms of HbA1c and 
weight, it is significantly more potent than a DPP4 inhibitor (sitagliptin), a SGLT-2 inhibitor 
(canaglifozin) and basal insulin (glargine). It has also been assessed in head-to-head 
comparisons with three GLP-1RAs (including both the other weekly agents, exenatide ER 
and dulaglutide) and been found to be significantly more efficacious in terms of both HbA1c 
and weight reduction. 
 
The CVOT for semaglutide (SUSTAIN 6) demonstrated the CV safety of this medicine and a 
significant 26% reduction in the primary end-point of 3-point MACE (albeit in a non-
prespecified analysis). 
 
The AE profile of semaglutide is as expected for a GLP-1RA therapy, with increased GI upset 
including nausea, vomiting and diarrhoea. These symptoms tend to diminish with time and 
are reduced by slow up-titration of drug. However, on balance there does appear to be 
more GI upset with semaglutide compared with other GLP-1RAs and this may affect 
adherence in clinical practice. The unexpected finding of an increase in retinopathy events 
in the SUSTAIN 6 trial may be explained by potent glucose lowering in patients with poor 
glycaemic control and pre-existing DR; caution should be urged when initiating semaglutide 








• Semaglutide is the most recently approved once weekly injectable GLP-1 receptor 
agonist for the treatment of type 2 diabetes 
• Semaglutide is more efficacious in reducing HbA1c and weight than other classes of 
glucose lowering therapies 
• Head-to-head comparisons with other GLP-1RAs, including exenatide ER and 
dulaglutide, show superiority of semaglutide for both HbA1c and weight reduction 
• The cardiovascular outcome trial for semaglutide showed both safety and a 
reduction in major cardiovascular events 
• Gastrointestinal side effects are commonly seen with semaglutide and may be more 
frequent than with other GLP-1RA therapies 
• Caution is needed when initiating semaglutide in patient with pre-existing diabetic 
retinopathy and poor glycaemic control 
 
Expert opinion:  
 
Glucagon-like peptide-1 receptor agonists (GLP-1Ras) are now a well-established class of 
injectable peptides for the management of people with type 2 diabetes (T2DM). They have a 
high level of efficacy in reducing hyperglycaemia and the secondary benefits of weight 
reduction and blood pressure lowering. Indeed, a high dose formulation of liraglutide is now 
licenced for the management of obesity. GLP-1RAs, which are based on the human GLP-1 
molecule (rather than exendin-4), have been shown to reduce major adverse cardiovascular 
events in people with T2DM and, as a result of these findings, are now positioned earlier in 
the treatment algorithm of people with T2DM and high cardiovascular risk. The side effects 
of GLP-1RAs are typically gastrointestinal (GI) with nausea, vomiting and diarrhoea, 
especially at the time of initiation. These can be limited by slow up-titration of drug and 
tend to diminish over time. Early concerns regarding rises in amylase and lipase and the 
potential for pancreatitis (and even pancreatic cancer) have not been realised (REF 40), nor 
has there been any clinical evidence of an increase in medullary thyroid cancer (which was 
seen in rodents during pre-clinical studies of liraglutide) (REF 41). 
 
Semaglutide is the most recently approved GLP-1RA and has 94% homology with human 
GLP-1. It is very similar to liraglutide, having one additional amino acid difference and a 
longer di-acid fatty chain, allowing for tight binding to albumin and the protracted duration 
of action. Semaglutide thus becomes forth once weekly GLP-1RA to be approved and is one 
of three currently marketed (albiglutide having been withdrawn for commercial reasons in 
2018 (REF 42). The use of once weekly GLP-1RAs is preferred by patients since it reduces the 
burden of injections and this is reflected in the increasing market share for these agents. 
Semaglutide has been trialled against both of the other weekly GLP-1RAs (exenatide ER and 
dulaglutide) and has been shown to be superior in both HbA1c and weight reduction. It also 
has a supportive cardiovascular outcomes trial (CVOT), which showed a significant 26% 
reduction in the primary composite end-point of cardiovascular death, nonfatal myocardial 
infarction and nonfatal stroke (albeit in a non-prespecified statistical analysis); the CVOT for 
dulaglutide (REWIND) was also positive, whilst that for exenatide ER narrowly missed 
significance. Based on these data, it seems likely that semaglutide will become the once 
weekly GLP-1RA of choice going forwards. 
 
Are there any downsides? There is a suggestion that the GI side-effects with semaglutide 
may be more frequent and possibly more severe than with the other GLP-RAs and this may 
impact on adherence. Also, the increased diabetic retinopathy events seen with semaglutide 
in SUSTAIN 6 will concern some prescribers. It is of note that no signal for retinopathy 
events was seen in the SUSTAIN 1-5 and 7 trials of semaglutide, which all had an upper limit 
of HbA1c for inclusion and excluded patients with active retinopathy. In our view, it is likely 
that the worsening of diabetic retinopathy reported in SUSTAIN 6 was related to rapid 
reduction of hyperglycaemia in subjects with poor glucose control and significant existing 
eye disease. This has been seen previously with insulin treatment and following bariatric 
surgery. It is also consistent with the non-significant increase in DR events seen in the CVOTs 
for both liraglutide and dulaglutide, which are also potent glucose-lowering medications. 
 
Other aspects will also impact on clinical decision-making, for example the injection 
preparation (problematic for exenatide ER, which requires vigorous shaking prior to 
injection) as well as the design of administration device, which may favour dulaglutide (REF 
43). And there is also the issue of cost, which will vary in different countries. Where the 
prices of the long-acting GLP-1RAs are equivalent, then health technology analyses are 
largely driven by HbA1c and weight and reflect differences in efficacy (REF 44). 
 
It is possible, however, that the biggest threat to the future dominance of semaglutide in 
the GLP-1RA market comes from itself. Oral semaglutide has been developed as a tablet, co-
formulated with an absorption enhancer known as SNAC (sodium N-(8-[2-hydroxylbenzoyl] 
amino) caprylate)(REF 45). SNAC facilitates the passage of semaglutide across the gastric 
mucosa via a transcellular mechanism, as well as providing a localised increase in pH which 
protects the semaglutide from degradation (REF 46). The pharmacokinetics of oral 
semaglutide allow for once daily dosing and the results from the phase 3 clinical trial 
programme (named PIONEER) are extremely impressive. Oral semaglutide is significantly 
more effective in reducing HbA1c than placebo (REF 47), sitagliptin (REF 48), empagliflozin 
(REF 49) and injected liraglutide (REF 50), as well as having a substantial impact of weight 
reduction. A CVOT of oral semaglutide (PIONEER 6)(REF 51,52) has shown cardiovascular 
safety and a superiority trial for CV events (SOUL) is on-going (REF 53). There is a possibility 
that the oral version of semaglutide, approved for use in the United States in 2019 and the 
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